

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No.	50304/014002
	Serial No.	10/595,293
	Applicant	VERBRUGGEN et al.
	Filing Date	April 5, 2006
	Group	1635
	IDS Filed	November 13, 2007
	Customer No.	21559

U.S. PATENT DOCUMENTS				
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)				
/J.P./	Bresnihan et al., "Treatment of Rheumatoid Arthritis with Recombinant Human Interleukin-1 Receptor Antagonist." Arthritis Rheum. 41:2196-2204 (1998)			
	Bresnihan & Cobby, "Clinical and Radiological Effects of Anakinra in Patients with Rheumatoid Arthritis." Rheumatology 42:Suppl 2, ii22-ii28. (2003)			
	Giannoukakis et al. "Adenoviral Gene Transfer of the Interleukin-1 Receptor Antagonist Protein to Human Islets Prevents IL-1beta-Induced Beta-Cell Impairment and Activation of Islet Cell Apoptosis In Vitro." Diabetes 48:1730-1736 (1998)			
	Jacobs et al., "Experimental Autoimmune Encephalomyelitis is Exacerbated by IL-1Alpha and Suppressed by Soluble IL-1 Receptor." J. Immunol. 146:2983-2989 (1991)			
	Jiang et al., "A Multicenter, Double-Blind, Dose-Ranging, Randomized, Placebo-Controlled Study of Recombinant Human Interleukin-1 Receptor Antagonist In Patients with Rheumatoid Arthritis: Radiologic Progression and Correlation of Genant and Larsen scores." Arthritis Rheum. 43:1001-1009 (2000)			
	Lim et al., "Local Expression of Interleukin-1 Receptor Antagonist by Plasmid DNA Improves Mortality and Decreases Myocardial Inflammation in Experimental Coxsackieviral Myocarditis." Circulation 105:1278-1281 (2002)			
	Maedler et al. "Glucose-Induced Beta-Cell Production of IL-1Beta Contributes to Glucotoxicity in Human Pancreatic Islets" J. Clin. Invest. 110:851-860 (2002)			
	Martin & Near, "Protective Effect of the Interleukin-1 Receptor Antagonist (IL-1ra) on Experimental Allergic Encephalomyelitis in Rats." J. Neuroimmunol. 61:241-245 (1995)			
	Moore et al., "The Inflammatory Milieu Associated with Conjunctivalized Cornea and Its Alteration with IL-1 RA			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50304/014002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/595,293
		Applicant	VERBRUGGEN et al.
		Filing Date	April 5, 2006
		Group	1635
		IDS Filed	November 13, 2007
(37 C.F.R. § 1.98(b))		Customer No.	21559

U.S. PATENT DOCUMENTS	
/J.P./	Gene Therapy." Invest. Ophthalmol. Vis. Sci. 43:2905-2915 (2002)
/J.P./	Rudinskaya & Trock, "Successful Treatment of a Patient with Refractory Adult-Onset Still Disease with Anakinra." Clin. Rheumatol. 9:330-332 (2003)
/J.P./	Yang et al., "Attenuation of Ischemic Inflammatory Response in Mouse Brain Using an Adenoviral Vector to Induce Overexpression of Interleukin-1 Receptor Antagonist." J. Cereb. Blood. Flow. Metab. 18:840-847 (1998)
/J.P./	Yokoo et al., "Genetically Modified Bone Marrow Continuously Supplies Anti-Inflammatory Cells and Suppresses Renal Injury in Mouse Goodpasture Syndrome." Blood 98:5764 (2001)

EXAMINER /Jennifer Pitrak/	DATE CONSIDERED 07/28/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	